Dore, Gregory J.

Publishing since 1995 (Senior)

Has published 119 publications in 16 years

Number of publications published per year by Dore, Gregory J.. (Source : PubMed)

Distribution of publications types for Dore, Gregory J.. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Day CA, White B, Dore GJ, van Beek I, Rodgers C, Cunningham P, Wodak A, Maher L. Hepatitis B virus among injecting drug users in Sydney, Australia: prevalence, vaccination and knowledge of status.  Drug Alcohol Depend  2010;108;1-2  
•  Dore GJ, Soriano V, Rockstroh J, Kupfer B, Tedaldi E, Peters L, Neuhaus J, Puoti M, Klein MB, Mocroft A, Clotet B, Lundgren JD. Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption.  AIDS  2010;24;6  
•  Crane M, Sirivichayakul S, Chang JJ, Avihingsanon A, Ubolyam S, Buranapraditkun S, Thantiworasit P, Wightman F, Locarnini S, Matthews G, Dore GJ, Ruxrungtham K, Lewin SR. No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy.  J. Virol.  2010;84;6  
•  Milner KL, van der Poorten D, Trenell M, Jenkins AB, Xu A, Smythe G, Dore GJ, Zekry A, Weltman M, Fragomeli V, George J, Chisholm DJ. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance.  Gastroenterology  2010;138;3  
•  Grebely J, Petoumenos K, Matthews GV, Haber P, Marks P, Lloyd AR, Kaldor JM, Dore GJ, Hellard M. Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study.  Drug Alcohol Depend  2010;107;2-3  
•  Grebely J, Raffa JD, Lai C, Kerr T, Fischer B, Krajden M, Dore GJ, Tyndall MW. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents.  J. Viral Hepat.  2010  
•  Dore GJ, Hellard M, Matthews GV, Grebely J, Haber PS, Petoumenos K, Yeung B, Marks P, van Beek I, McCaughan G, White P, French R, Rawlinson W, Lloyd AR, Kaldor JM. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection.  Gastroenterology  2010;138;1  
•  Grebely J, Matthews GV, Petoumenos K, Dore GJ. Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infection.  J. Viral Hepat.  2009  
•  Topp L, Day C, Dore GJ, Maher L. Poor criterion validity of self-reported hepatitis B infection and vaccination status among injecting drug users: a review.  Drug Alcohol Rev  2009;28;6  
•  Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.  Nat. Genet.  2009;41;10  

[ See timeline ] [ See all publications ]